A molecular toolkit for the functionalization of titanium-based biomaterials that selectively control integrin-mediated cell adhesion by Rechenmacher, Florian et al.
Supporting Information
 Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2013
A Molecular Toolkit for the Functionalization of Titanium-Based
Biomaterials That Selectively Control Integrin-Mediated Cell Adhesion
Florian Rechenmacher,[a] Stefanie Neubauer,[a] Carlos Mas-Moruno,[a, g]
Petra M. Dorfner,[b] Julien Polleux,[c] Judith Guasch,[d] Bert Conings,[e]
Hans-Gerd Boyen,[e] Alexander Bochen,[a] Tariq R. Sobahi,[f] Rainer Burgkart,[b]
Joachim P. Spatz,[d] Reinhard Fssler,[c] and Horst Kessler*[a, f]
chem_201301478_sm_miscellaneous_information.pdf
 S2
Table of Contents 
 
Methods 
Supplementary Figures 
General Procedures and Synthesis 
References 
 S3
Methods 
Nanopatterned titanium dioxide surfaces  
In a typical synthesis, polystyrene(x)-block-poly(2-vinylpyridine)(y) (PSx-b-P2VPy, 
where x=846 and y=171 represent the number of monomer units) from Polymer 
Source Inc. was dissolved at room temperature in anhydrous benzyl alcohol 
(BnOH, Sigma-Aldrich) and stirred for 1 day. The quantity of inorganic precursor 
was calculated relative to the number of P2VP units (NP2VP) and defined as the 
loading parameter (L). L was kept constant in all experiments, equal to 0.5, i.e., 1 
molecule of TiCl4 for 2 P2VP monomers. For the preparation of titanium dioxide 
solutions, 2.2 µL of titanium tetrachloride (TiCl4, Sigma-Aldrich) was dissolved 
under nitrogen in 5 mL of BnOH. The solution was heated for 5 min at 70 °C in 
an oil bath for better dissolution. Upon stirring at room temperature for 3 hours, 
25 mg of PSx-b-P2VPy was added to the solution and stirred 15 hours at room 
temperature. In order to induce TiO2 particle formation, the solution was stirred at 
70 °C for 5 days. After aging the solution for three weeks at room temperature, a 
yellow solution was obtained. Glass cover slips (Carl Roth) were cleaned in a 
piranha solution for at least 5 hours and were extensively rinsed with MilliQ water 
and dried under a stream of nitrogen. Micellar monolayers were prepared by dip-
coating a glass cover slip into the previously prepared solutions with a constant 
velocity equal to 24 mm·min-1. The samples were dried in an oven at 80 °C for 
120 min. Finally, to remove the organic template and to form inorganic 
nanoparticles, the dip-coated glass slides were exposed to oxygen plasma 
(150W, 0.15 mbar, 45 min, PVA TEPLA 100 Plasma System). 
To prevent nonspecific protein adsorption or cell binding, the substrate area 
surrounding the nanoparticles was covalently modified with silane-terminated 
polyethylene glycol (PEG; molecular weight 2000). The TiO2 nanoparticles were 
then functionalized with peptidomimetics by incubating the PEG-functionalized 
substrates in 60 µL of a 100 µM aqueous solution. The substrates were then 
thoroughly rinsed with water, incubated overnight in water, and finally dried with 
nitrogen. 
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Cell experiments  
Mouse fibroblast cell lines expressing either αvβ3 or α5β1 were generated from 
fibroblasts derived from the kidney of αvflox/flox, β1flox/flox, β2-/- , β7-/- mice 
(manuscript in preparation). Cells were immortalized by retroviral transduction of 
the SV40 large T and cloned. Subsequently the cells were retrovirally transduced 
with mouse αv or β1 integrin expression constructs. Endogenous β1 and αv 
integrin loci were deleted by adenoviral cre-recombinase transduction. Selective 
expression of αvβ3 or α5β1 was verified by flow cytometry and immunoblotting. 
Single integrin-expressing fibroblasts were cultivated by using DMEM 
supplemented with 10% FBS (both from Gibco, Invitrogen, Darmstadt, Germany), 
1% penicillin / streptomycin (PAA, Cölbe, Germany) in a culture incubator at 
37 °C in an atmosphere containing 5 % CO2. After reaching 80% confluence, 
cells were first rinsed with sterile PBS and then released with a 1% trypsin-EDTA 
solution (Gibco, Invitrogen, Darmstadt, Germany) for about 3-5 minutes. 
Trypsinisation was stopped by adding 10% FBS supplemented DMEM to the 
released cells, which were centrifuged at 900 rpm for 3 minutes. The resulting 
cell pellet was resuspended in pre-warmed growth medium and the cells were 
seeded again in cell culture dishes. 
To test the selectivity of the compounds, both cells lines were trypsinised, 
resuspended in DMEM containing 0.5 % FBS and seeded (approximately 2.103 
cells) on functionalized titanium dioxide nanoarrays. Live cell imaging was 
performed at 37°C and 5% CO2 on a Zeiss Axiovert 200M microscope with a 10× 
1.6 objective; the microscope was equipped with a motorized stage (Märzhäuser, 
Wetzlar, Germany), an environment chamber (EMBL Precision Engineering, 
Heidelberg, Germany) and a cooled CCD camera (Roper Scientific, Princeton, 
NJ). Spreading area was manually quantified with ImageJ (version 1.43u)1 on a 
population of 50 cells. Error bars correspond to the standard deviation. 
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Competitive solid phase integrin binding assay2 
The in vitro inhibition of integrin–extracellular matrix protein binding was 
measured using a solid phase binding assay with soluble integrins and coated 
extracellular matrix ligands. Human integrin αvβ3
 
was purchased from Millipore 
and α5β1
 
from R&D Systems. Vitronectin was purchased from Millipore and 
fibronectin from Sigma. The integrin antibodies were purchased from 
Pharmingen, BD Bioscience Europe (mouse anti-human CD49e, mouse anti-
human CD51/CD61 and mouse anti-human CD41b) and Sigma (anti-mouse IgG-
peroxidase). The detection of HRP was performed using HRP substrate solution 
3.3.5.5’-tetramethylethylenediamine (TMB, Seramun, Germany) and 3 M H2SO4 
for stopping the reaction. The absorbance (450 nm) was recorded with a 
POLARstar Galaxy plate reader (BMG Labtechnologies). Every concentration 
was analyzed in duplicates and the resulting inhibition curves were analyzed 
using OriginPro 7.5G software, the turning point describes the IC50 value. Each 
plate contained Cilengitide3 as internal control. Blocking and binding steps were 
always performed with TS buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
CaCl2, 1 mM MgCl2, and 1 mM MnCl2) containing 1% BSA (TSB-buffer). 
Washings after each incubation step were done with PBST buffer (10 mM 
Na2HPO4 pH 7.5, 150 mM NaCl, and 0.01% Tween 20). 
Fibronectin-α5β1 assay. Flat-bottom 96-well ELISA plates were coated 
overnight at 4 °C with 100 µL/well of 0.50 µg/mL of fibronectin in 15 mM of 
Na2CO3, 35 mM NaHCO3, pH 9.6 (carbonate buffer). Plates were subsequently 
blocked for 1 h at room temperature. Next, 1.0 µg/mL of soluble integrin α5β1 
and a serial dilution of integrin inhibitors and the control Cilengitide were 
incubated in the coated wells for 1 h at room temperature. After washing three 
times, the plate was treated with 100 µL/well of primary antibody (CD49e) at 1.0 
µg/mL (1:500 dilution) and secondary antibody (anti-mouse IgG-peroxidase) at 
2.0 µg/mL (1:385 dilution) for 1 h each at room temperature. After this treatment 
the plate was washed three times and the binding visualized with TMB as 
previously described.  
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Vitronectin-αvβ3 assay. For the αvβ3 assay, plates were coated with vitronectin 
(1.0 µg/mL) in carbonate buffer and blocked as described for α5β1. Soluble αvβ3 
(1.0 µg/mL) was incubated with a serial dilution of integrin inhibitors and the 
control Cilengitide for 1 h at room temperature. After washing three times, 
primary (CD51/CD61, 2.0 µg/mL, 1:250 dilution) and secondary antibody (anti-
mouse-HRP conjugate, 1.0 µg/mL, 1:770 dilution) were applied for 1 h each at 
room temperature and the binding visualized as explained for α5β1.  
 
Integrin binding assay on coated Ti6Al4V disks4 
αvβ3-binding assay. Ti6Al4V disks were coated overnight at room temperature 
(RT) with 100 µL/disk of peptide solutions (100 µM) in PBS. Disks were 
subsequently washed three times with PBST buffer (PBS + 0.01% (v/v) Tween 
20) and blocked for 2 h at 30 °C with 100 µL/disk of TSB-buffer (20 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, 1% (w/v) of 
bovine serum albumin [BSA]). Next, disks were washed three times with PBST 
and incubated with 100 µL of 10 µg/mL human biotinylated-αvβ3 integrin 
(Millipore, Schwalbach, Germany) in TSB for 2 h at 30 °C. Biotinylation of the 
integrin was done in-house with sulfo-NHS-LC-LC-Biotin (Pierce, Rockford, IL, 
USA, 20:1 molar ratio). After five washes in PBST, disks were treated with 100 
µL/disk of 0.25 µg/mL NeutrAvidin-horseradish peroxidase conjugate in TSB for 1 
h at 30 °C. Finally, disks were washed five times and the binding was visualized 
with TMB as previously described. For measurement of the absorbance, the 
solutions were transferred into a flat-bottom 96-well ELISA plate. 
α5β1-binding assay. Ti6Al4V disks were coated overnight at room temperature 
(RT) with 100 µL/disk of peptide solutions (100 µM) in PBS. Disks were 
subsequently washed three times with PBST buffer (PBS + 0.01% (v/v) Tween 
20) and blocked for 2 h at 30 °C with 100 µL/disk of TSB-buffer (20 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, 1% (w/v) of 
bovine serum albumin [BSA]). Next, disks were washed three times with PBST 
and incubated with 100 µL of 10 µg/mL soluble integrin α5β1 in TSB for 2 h at 
room temperature. After five washes in PBST, disks were treated with 100 
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µL/disk 100 µL/disk of primary antibody (CD49e) at 1.0 µg/mL (1:500 dilution) 
and secondary antibody (anti-mouse IgG-peroxidase) at 2.0 µg/mL (1:385 
dilution) for 1 h each at room temperature. Finally, disks were washed five times 
and the binding was visualized with TMB as previously described. 
 
X-ray photoelectron spectroscopy (XPS) 
Continuous layers of TiO2 (200 nm) were sputtered on clean glass and annealed 
at 150 oC for 3 minutes. Then, the substrates were incubated with 8 (25 µM in 
water) at room temperature using different incubation times. After rinsing the 
functionalized substrates with water, XPS spectra were measured using a 
commercial Physical Electronics PHI-5600LS photoelectron spectrometer, with 
monochromatized Al-Kα X-rays (photon energy 1486.6 eV). The spot size of the 
beam was about 1 mm2, and photoelectrons were measured with a pass energy 
of 58 eV.  
 
Quartz crystal microbalance with dissipation monitoring (QCM-D) 
QCM-D measurements (model Q-sense E4, Q-sense AB, Göteborg, Sweden) 
were performed on a gold sensor (Q-sense, Göteborg, Sweden) sputtered with 
titanium (50 nm), whose native oxide layer was cleaned by sonication with 
ethanol 99.98% for 15 minutes. The flow rate and temperature were kept 
constant at 100 µL/min and 22 oC during the experiment. Changes in the 
resonance frequency, ∆f, and dissipation, ∆D, were simultaneously monitored as 
a function of time at different overtones (n = 3-11). After establishing a stable 
baseline with water, we flowed compound 8 (25 µM in water) which resulted in a 
frequency shift that indicates the adsorption of the molecule on the substrate 
(Figure S1). After approximately 10 minutes, equilibrium was reached with ∆f = - 
9.6 Hz. This adsorption was not affected by the subsequent water wash, 
indicating the absence of physisorbed molecules or detachment from the 
substrate. The Sauerbrey equation5 was demonstrated to be valid for this 
experiment in agreement with the dissipation response, which remained virtually 
unchanged at zero (∆D < 1x10-6). Therefore, it can be concluded that compound 
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8 forms a rigid film on TiO2 layers with an equilibrium adsorbed mass of 24 
ng/cm2 (QSoft401 v.2.5.2.418 and QTools v.3.0.17.560). 
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Supplementary figures 
 
Water wash Water washCoating with 8
 
Figure S1: QCM-D measurement (7th overtone) of a gold sensor sputtered with 
titanium (50 nm) upon adsorption of 8 (25 µM in water, 100 µL/min). 
 
 
 
Figure S2: Diagram displaying the spreading area of α5β1- and αvβ3-expressing 
cells after 4h in culture on titanium dioxide nanoarrays functionalized with α5β1- 
and αvβ3-selective compounds. The number of analyzed cells for each 
population is n = 50. 
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Figure S3: Diagram displaying the percentage of spread and round cells 
expressing α5β1 or αvβ3 integrin on titanium dioxide nanoarrays functionalized 
with α5β1- or αvβ3-ligands in culture for 4h. A population of about 300 cells has 
been considered. 
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General Procedures and Synthesis  
Solvents and Reagents. Solvents were purchased from Aldrich, Fluka, Merck 
and Prolabo. Reactions sensible to oxygen or water were performed in flame-
dried reaction vessels under an argon atmosphere (99.996%). Protected Fmoc-
amino acids and coupling reagents were purchased from Novabiochem 
(Schwalbach, Germany), Iris Biotech GmbH (Marktredwitz, Germany) and 
Medalchemy (Alicante, Spain). All other chemicals and organic solvents were 
purchased from commercial suppliers at the highest purity available and used 
without further purification. Flash chromatographic purification was performed 
using silica gel 60 (40-63 µm) from Merck at 1-1.5 atm pressure. 
Analysis. Analytical high-performance liquid chromatography (HPLC) was 
performed using an Amersham Pharmacia Biotech Äkta Basic 10F equipment, 
with a P-900 pump system, a reversed-phase YMC-ODS-A C18 column (4.6 × 
250 mm, 5 µm), and UV detection (UV-900, 220 and 254 nm). The system was 
run at a flow rate of 1.0 ml/min over 30 min using H2O (0.1% (v/v) trifluoroacetic 
acid, [TFA]) and MeCN (0.1% (v/v) TFA) as solvents. Semi-preparative HPLC 
was carried out on a Beckmann instrument (system gold, solvent delivery module 
126, UV detector 166) using an YMC ODS-A column (20 × 250 mm, 5 µm), at a 
flow rate of 8 ml/min. Linear gradients using H2O (0.1% (v/v) TFA) and MeCN 
(0.1% (v/v) TFA) were run over varying periods of time. HPLC-mass 
spectrometry (MS) analyses were performed on a Hewlett Packard Series HP 
1100 with a Finnigan LCQ mass spectrometer using a YMC Hydrosphere C18 
column (2.1 ×125 mm, 3 µm). The system uses H2O (0.1% (v/v) formic acid) and 
MeCN (0.1% (v/v) formic acid) as eluents. High resolution mass spectrometry 
(HR-MS) was recorded on a Thermo Finnigan LTQ-FT (ESI-ICR) spectrometer. 
1H-NMR and 13C NMR spectra were recorded at 295 K on a 500 MHz Bruker 
DMX, 360 MHz Bruker AV or a 250 MHz Bruker AV spectrometer (Bruker, 
Karlsruhe, Germany). Chemical shifts (δ) are given in parts per million (ppm). 
Following solvent peaks were used as internal standards: dimethyl sulfoxide 
(DMSO)-d5: 2.50 ppm (1H-NMR) and 39.52 ppm (13C-NMR); CHCl3: 7.26 ppm 
(1H-NMR) and 77.16 ppm (13C-NMR).6 
 S12
GP1 Loading of tritylchloride (TCP) resin. Solid phase synthesis was carried 
out using TCP resin (0.94 mmol/g) following standard Fmoc strategy. Fmoc-Aax-
OH (1.2 eq.) was attached to the TCP resin with N,N-diisopropylethylamine 
(DIEA, 2.5 eq.) in anhydrous DCM (10 ml/g resin) at room temperature for 1 h. 
The remaining trityl chloride groups were capped by addition of a solution of 
MeOH/DIEA (4/1, v/v, 1 ml/g resin) for 15 min. The resin was filtered and washed 
thoroughly with DCM (2x), N-methyl-2-pyrrolidone (NMP, 3x) and MeOH (5x). 
The loading capacity was determined by weight after drying the resin under 
vacuum. 
GP2 Solid phase N-Fmoc deprotection. The resin-bound Fmoc peptide was 
treated with 20% piperidine in NMP (v/v) for 5 min and a second time for 10 min. 
The resin was washed with NMP (5x). 
GP3 Solid phase coupling with HATU/HOAt. A solution of the acid (2 eq.), 
HATU (2 eq.), HOAt (2 eq.), DIEA (5 eq.) in NMP was added to the resin-bound 
free amine peptide and shaken for 1.5 h at room temperature. The resin was 
washed with NMP (5x). 
GP4 Solid phase N-Alloc deprotection. The resin was washed with DCM (3x) 
and then treated with a solution of tetrakis-triphenylphosphinepalladium (0.25 
eq.) and phenylsilane (10 eq.) in DCM at ambient temperature. Care had to be 
taken due to gas evolution and the pressure had to be released from the reaction 
vessel from time to time. After 30 min of shaking, the mixture was filtered and the 
resin washed twice with a 0.5% solution of DDTC (sodium N,N-
diethyldithiocarbamate) in DMF and a 0.5% solution of DIEA in DMF. The 
washing procedure was repeated (3x) and the resin washed with NMP (5x). 
GP5 Guanidinylation. The amino-functionalized resin was added to a solution of 
10 eq. N,N’-bis-Boc-guanidinylpyrazole in absolute DCM (10 ml/g resin) in a 
closed reaction vessel. The mixture was shaken over night at room temperature. 
The resin was filtered and washed five times with DCM. The unconsumed 
guanidinylpyrazole could be recycled by concentration of the filtrate and 
recrystallization from hexane/ethyl acetate. 
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GP6 Cleavage from TCP resin. The resin-bound compound was treated three 
times with a 20% solution of HFIP (hexafluoroisopropanol) in DCM (v/v) for 10 
min. The collected solutions were concentrated in vacuo. 
GP7 Boc, tBu and trityl deprotection in solution. Deprotection was achieved 
by treatment with TFA/TIS/H2O (95/2.5/2.5, v/v/v) in solution for 1 h. The mixture 
was coevaporated with toluene (3x). 
GP8 Copper catalyzed Azide-Alkyne Cycloaddtion (CuAAC). The azide and 
the alkyne were dissolved in 2 mL H2O/tBuOH (1:1), CuSO4·5H2O (1.2 eq.) and 
Cu (40 eq.) added and the reaction mixture stirred for 16 h at r.t. After filtration 
the solvent is evaporated under reduced pressure. 
GP9 Coupling with HATU/HOAt in solution. A solution of the acid (1 eq.), the 
amine (1 eq.), HATU (1.3 eq.), HOAt (1.3 eq.) and DIEA (5 eq.) in DMF was 
stirred overnight. After removing the DMF under reduced pressure, the residue 
was redissolved in EtOAc, washed consecutively with saturated NH4Cl, saturated 
NaHCO3 and brine and dried over Na2SO4. After evaporation of the solvent the 
crude product was purified by reverse phase HPLC to afford the final compound. 
GP10 Acetylation of amines on solid support. The resin was washed with 
DCM (3x) and treated with a solution (10 mL/g resin) of acetic 
anhydride/DCM/DIEA (25:72.5:2.5) for 30 min. After filtration the resin was 
washed with DCM (5x). 
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(S)-3-(2-(3-guanidinobenzamido)acetamido)-2-(4-isopropoxy-2,6-
dimethylbenzamido)propanoic acid) (1) 
 
Preparation of compound 1 according to literature7 gave 15.13 mg (26 µmol, 
22%) as colorless solid. 1H-NMR (500 MHz, DMSO): δ = 12.71 (bs, 1H), 9.95 
(bs, 1H), 8.79 (t, 3J = 5.8 Hz, 1H), 8.27 (d, 3J = 6.6 Hz, 1H), 8.02 (t, 3J = 5.7 Hz, 
1H), 7.77 (d, 3J = 7.9 Hz, 1H), 7.73 (s, 1H), 7.55-7.42 (m, 4H), 7.39 (d, 
3J = 9.1 Hz, 1H), 6.57 (s, 2H), 4.62-4.56 (m, 1H), 4.50-4.46 (m, 1H), 3.98-3.87 
(m, 3H), 3.91 (dd, 2J = 16.3 Hz, 3J = 5.9 Hz, 1H),  3.83 (dd, 2J = 16.3 Hz, 
3J = 5.8 Hz, 1H), 3.56-3.51 (m, 1H), 3.44-3.39 (m, 1H), 2.20 (s, 6H), 1.24 (d, 
3J = 6.0 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δ = 171.9, 169.2, 165.7, 156.9, 
155.8, 135.7, 135.6, 135.4, 130.6, 129.7, 127.2, 125.2, 123.4, 114.0, 68.8, 52.0, 
42.5, 21.8, 19.1. RP-HPLC (10-90%, 30 min) Rt = 13.50 min. MS (ESI): m/z = 
513.2 [m+H]+, 535.2 [m+Na]+. HR-MS (ESI) calc. for C25H33N6O6+: 513.24561; 
found: 513.24585. 
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(S)-2-(4-(3-(5-azidopentanamido)propoxy)-2,6-dimethylbenzamido)-3-(2-(3-
guanidinobenzamido)acetamido)propanoic acid (2) 
 
Prepared from N-α-Fmoc-N-β-Alloc-L-diaminopropionic acid according the 
following reaction sequence: Loading of 700 mg resin (real loading: ~540 µmol, 
GP1), Fmoc deprotection (GP2), coupling of 4-(4-(9H-fluoren-9-yl)methyl)-
carbaminobutoxy)-2,6-dimethylbenzoic acid (GP3), Fmoc deprotection (GP2), 
coupling of 5-Azidpentanoic acid (GP3), Alloc deprotection (GP4), coupling of 
Fmoc-Gly-OH (GP3), Fmoc deprotection (GP2), coupling of 3-Fmoc-
aminobenzoic acid (GP3), Fmoc deprotection (GP2), guanidinylation (GP5), 
cleavage from the resin (GP6), Trityl and Boc deprotection (GP7). After 
semipreparative HPLC purification compound 2 (54.5 mg, 83.5 µmol, 16%) was 
obtained as colorless solid.  
1H-NMR (500 MHz, DMSO-d6): δ = 12.77 (bs, 1H),9.88 (s, 1H), 8.81 (t, 3J = 
5.9 Hz, 1H), 8.37 (d, 3J = 7.7 Hz, 1H), 8.04 (t, 3J = 5.9 Hz, 1H), 7.91 (t, 
3J = 5.6 Hz, 1H), 7.77 (d, 3J = 8.0 Hz, 1H), 7.72 (s, 1H), 7.56-7.52 (m, 4H), 7.40 
(d, 3J = 8.0 Hz, 1H), 6.58 (s, 2H), 4.53-4.49 (m, 1H), 3.97-3.88 (m, 3H), 3.82 (dd, 
2J = 16.3 Hz, 3J = 5.5 Hz, 1H), 3.59-3.54 (m, 1H), 3.40-3.37 (m, 1H), 3.32 (t, 
3J = 6.6 Hz, 2H), 3.17 (q, 3J = 6.6 Hz, 2H), 2.21 (s, 6H), 2.09 (t, 3J = 6.6 Hz, 2H), 
1.84-1.78 (m, 2H), 1.56-1.48 (m, 4H). 13C NMR (126 MHz, DMSO-d6) δ = 171.8, 
171.8, 169.3, 169.2, 165.7, 158.1, 155.8, 135.8, 135.6, 135.4, 130.7, 129.8, 
127.4, 125.2, 123.5, 112.9, 65.1, 52.0, 50.4, 42.5, 35.4, 34.8, 29.0, 27.9, 22.5, 
19.2. RP-HPLC (10-90%, 30 min) Rt = 13.19 min. MS (ESI): m/z = 653.3 [m+H]+. 
HR-MS (ESI) calc. for C30H41N10O7+: 653.31542; found: 653.31490. 
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(S)-2-(2,6-Dimethyl-4-(3-(5-(4-((3-phosphonopropanamido)methyl)-1H-1,2,3-
triazol-1-yl)pentanamido)propoxy)benzamido)-3-(2-(3-
guanidinobenzamido)acetamido)propanoic acid (3) 
Prepared from 2 (8.79 mg, 13.5 µmol, 1 eq.) and 15 (5.00 mg, 13.5 µmol, 1 eq.) 
according to GP8 and deprotected according to GP7. After semipreparative 
HPLC purification compound 3 (3.58 mg, 4.24 µmol, 31%) was obtained as 
colorless solid. 
RP-HPLC (10-90%, 30 min) Rt = 9.11 min. MS (ESI): m/z = 844.4 [m+H]+, 866.3 
[m+Na]+. HR-MS (ESI) calc. for C36H51N11O11P+: 844.35016; found: 844.35114. 
 
 
(S)-2-(4-(3-(5-(4-(((S)-2-Acetamido-6-(3-
phosphonopropanamido)hexanamido)-methyl)-1H-1,2,3-triazol-1-
yl)pentanamido)propoxy)-2,6-dimethylbenzamido)-3-(2-(3-
guanidinobenzamido)acetamido)propanoic acid (4) 
Prepared from 2 (10.00 mg, 16.8 µmol, 1 eq.) and 16 (9.10 mg, 16.8 µmol, 1 eq.) 
according to GP8 and deprotected according to GP7. After semipreparative 
HPLC purification compound 4 (3.65 mg, 3.6 µmol, 21%) was obtained as 
colorless solid. 
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RP-HPLC (10-90%, 30 min) Rt = 9.02 min. MS (ESI): m/z = 1014.6 [m+H]+, 
1036.5 [m+Na]+. HR-MS (ESI) calc. for C44H65N13O13P+: 1014.4562; found: 
1014.4537. 
 
 
(S)-2-(4-(3-(5-(4-(((S)-6-Acetamido-2-(3-
phosphonopropanamido)hexanamido)-methyl)-1H-1,2,3-triazol-1-
yl)pentanamido)propoxy)-2,6-dimethylbenzamido)-3-(2-(3-
guanidinobenzamido)acetamido)propanoic acid (5) 
Prepared from 2 (7.70 mg, 11.8 µmol, 1 eq.) and 17 (6.40 mg, 11.8 µmol, 1 eq.) 
according to GP8 and deprotected according to GP7. After semipreparative 
HPLC purification compound 5 (2.00 mg, 2.0 µmol, 17%) was obtained as 
colorless solid. 
RP-HPLC (10-90%, 30 min) Rt = 9.17 min. MS (ESI): m/z = 1014.6 [m+H]+, 
1036.6 [m+Na]+. HR-MS (ESI) calc. for C44H65N13O13P+: 1014.4562; found: 
1014.4546. 
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(S)-2-(4-(3-(5-(4-(((S)-2,6-bis(3-
phosphonopropanamido)hexanamido)methyl)-1H-1,2,3-triazol-1-
yl)pentanamido)propoxy)-2,6-dimethylbenzamido)-3-(2-(3-
guanidinobenzamido)acetamido)propanoic acid (6) 
Prepared from 2 (7.50 mg, 11.5 µmol, 1 eq.) and 18 (9.35 mg, 11.5 µmol, 1 eq.) 
according to GP8 and deprotected according to GP7. After semipreparative 
HPLC purification compound 6 (2.50 mg, 2.26 µmol, 20%) was obtained as 
colorless solid. 
RP-HPLC (10-90%, 30 min) Rt = 8.80 min. MS (ESI): m/z = 1108.5 [m+H]+, 
1130.5 [m+Na]+. HR-MS (ESI) calc. for C45H68N13O16P2+: 1108.4382; found: 
1108.4334. 
 
 
(S)-2-(4-(3-(5-(4-(((S)-6-((S)-2-Acetamido-6-(3-
phosphonopropanamido)hexan-amido)-2-((S)-2,6-
diacetamidohexanamido)hexanamido)methyl)-1H-1,2,3-triazol-1-
yl)pentanamido)propoxy)-2,6-dimethylbenzamido)-3-(2-(3-guanidinobenz-
amido)acetamido)propanoic acid (7) 
Prepared from 2 (5.18 mg, 7.9 µmol, 1 eq.) and 19 (7.00 mg, 7.9 µmol, 1 eq.) 
according to GP8 and deprotected according to GP7. After semipreparative 
HPLC purification compound 7 (2.44 mg, 1.8 µmol, 23%) was obtained as 
colorless solid. 
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RP-HPLC (10-90%, 30 min) Rt = 9.45 min. MS (ESI): m/z = 1352.8 [m+H]+, 
1345.6 [m+Na]+. HR-MS (ESI) calc. for C60H93N17O7P+: 1354.66675; found: 
1354.67322. 
 
 
(S)-2-(4-(3-(5-(4-(((S)-6-((S)-2,6-bis(3-Phosphonopropanamido)hexanamido)-
2-((S)-2,6-diacetamidohexanamido)hexanamido)methyl)-1H-1,2,3-triazol-1-
yl)pen-tanamido)propoxy)-2,6-dimethylbenzamido)-3-(2-(3-
guanidinobenzamido)acetamido)propanoic acid (8) 
Prepared from 2 (5.00 mg, 7.7 µmol, 1 eq.) and 20 (8.86 mg, 7.7 µmol, 1 eq.) 
according to GP8 and deprotected according to GP7. After semipreparative 
HPLC purification compound 8 (2.02 mg, 1.4 µmol, 18%) was obtained as 
colorless solid. 
RP-HPLC (10-90%, 30 min) Rt = 9.25 min. MS (ESI): m/z = 1448.7 [m+H]+, 
1471.5 [m+Na]+. HR-MS (ESI) calc. for C61H96N17O20P2+: 1448.6493; found: 
1448.6487. 
 
 
 
 
 
 
 
 
 
 S20
(S)-2-(4-(3-(5-(4-(((S)-2-((S)-6-acetamido-2-(3-
phosphonopropanamido)hexanamido)-6-((S)-2,6-bis(3-
phosphonopropanamido)hexanamido)hexanamido)-methyl)-1H-1,2,3-
triazol-1-yl)pentanamido)propoxy)-2,6-dimethylbenzamido)-3-(2-(3-
guanidinobenzamido)acetamido)propanoic acid (9) 
 
Prepared from 2 (5.00 mg, 7.7 µmol, 1 eq.) and 21 (10.97 mg, 7.7 µmol, 1 eq.) 
according to GP8 and deprotected according to GP7. After semipreparative 
HPLC purification compound 9 (1.65 mg, 1.1 µmol, 14%) was obtained as 
colorless solid. 
RP-HPLC (10-90%, 30 min) Rt = 8.65 min. MS (ESI): m/z = 1542.6 [m+H]+, 
1564.8 [m+Na]+. HR-MS (ESI) calc. for C62H99N17O23P3+: 1542.6313; found: 
1542.6295. 
 
 
 
 
 
 
 
 
 
 
 
 
 S21
(S)-2-(4-(3-(5-(4-(((S)-2,6-bis((S)-2,6-bis(3-Phosphonopropanamido)hexan-
amido)hexanamido)methyl)-1H-1,2,3-triazol-1-yl)pentanamido)propoxy)-2,6-
dimethylbenzamido)-3-(2-(3-guanidinobenzamido)acetamido)propanoic 
acid (10) 
 
Prepared from 2 (5.00 mg, 7.7 µmol, 1 eq.) and 22 (11.01 mg, 7.7 µmol, 1 eq.) 
according to GP8 and deprotected according to GP7. After semipreparative 
HPLC purification compound 10 (0.80 mg, 0.5 µmol, 7%) was obtained as 
colorless solid. 
RP-HPLC (10-20%, 30 min) Rt = 19.11 min. MS (ESI): m/z = 1634.7 [m-H]-. HR-
MS (ESI) calc. for C63H102N17O26P4+: 1636.6132; found: 1636.6132. 
 
 
(S)-2-(4-(3-(5-(4-(((S)-2-Acetamido-6-((S)-2-acetamido-6-(3-
phosphonopropanamido)hexanamido)hexanamido)methyl)-1H-1,2,3-triazol-
1-yl)pentanamido)-propoxy)-2,6-dimethylbenzamido)-3-(2-(3-
guanidinobenzamido)acetamido)propanoic acid (11) 
Prepared from 2 (4.70 mg, 7.2 µmol, 1 eq.) and 23 (5.12 mg, 7.2 µmol, 1 eq.) 
according to GP8 and deprotected according to GP7. After semipreparative 
HPLC purification compound 11 (1.65 mg, 1.1 µmol, 14%) was obtained as 
colorless solid. 
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RP-HPLC (10-90%, 30 min) Rt = 9.22 min. MS (ESI): m/z = 1184.5 [m+H]+, 
1206.5 [m+Na]+. HR-MS (ESI) calc. for C52H79N15O15P+: 1184.56122; found: 
1184.56646. 
 
 
(S)-3-(4-isopropoxybenzamido)-4-(4-(3-((4-methoxypyridin-2-
yl)amino)propoxy)phenyl)butanoic acid (12) 
N
O
N
H
O
COOH
HN O
O
C29H35N3O6
Exact Mass: 521.25
Mol. Wt.: 521.6
 
Preparation of compound 1 according to literature8 gave 32.7 mg (62.7 µmol, 
9%) as colorless solid. 1H-NMR (500 MHz, DMSO): δ [ppm] = 12.87 (bs, 1H), 
12.17 (bs, 1H), 8.28 (bs, 1H), 8.13 (d, 3J = 8.3 Hz, 1H), 7.80 (d, 3J = 7.1 Hz, 1H), 
7.72 (d, 3J = 8.8 Hz, 2H), 7.13 (d, 3J = 8.5 Hz, 2H), 6.94 (d, 3J = 8.8 Hz, 2H), 6.83 
(d, 3J = 8.6 Hz, 2H), 6.46 (dd, 3J = 7.0 Hz, 4J = 2.1 Hz, 1H), 6.33 (d, 4J = 1.9 Hz, 
1H), 4.72-4.65 (m, 1H), 4.44-4.37 (m, 1H), 4.01 (t, 3J = 6.0 Hz, 2H), 3.86 (s, 3H), 
3.46-3.42 (m, 2H), 2.80 (dd, 2J = 13.6 Hz, 3J = 8.0 Hz, 1H), 2.73 (dd, 2J = 13.6 
Hz, 3J = 5.8 Hz, 1H), 2.52-2.48 (m, 1H), 2.41 (dd, 2J = 15.4 Hz, 3J = 6.2 Hz, 1H), 
2.02-1.97 (m, 2H), 1.27 (d, 3J = 6.0 Hz, 6H). 13C-NMR (125 MHz, DMSO): δ 
[ppm] = 172.5, 165.1, 159.7, 156.8, 130.9, 130.1, 129.0, 126.5, 114.7, 114.1, 
103.9, 99.4, 69.3, 64.6, 56.4, 48.3, 40.1, 39.8, 38.7, 27.9, 21.7. RP-HPLC (10-
90%): tR = 17.63 min. MS (ESI): m/z (%) = 522.4 [m+H]+. HR-MS (ESI) calc. for 
C29H36N3O6+: 522.25986; found: 522.25795. 
 
 
 
 
 S23
(S)-3-(4-(3-(5-azidopentanamido)propoxy)benzamido)-4-(4-(3-((4-
methoxypyridin-2-yl)amino)propoxy)phenyl)butanoic acid (13) 
 
(S)-methyl-3-((tert-butoxycarbonyl)amino)-4-(4-(3-((4-methoxypyridin-2-
yl)amino)propoxy)phenyl)butanoate7 (33.0 mg, 69.7 µmol, 1 eq.) was 
deprotected according to GP7, coupled with 4-(3-(5-
azidopentanamido)propoxy)benzoic acid (26.8 mg, 83.6 µmol, 1.2 eq., GP9) and 
saponified with LiOH (5 eq.) in 5 mL MeOH/H2O (3/1 v/v). After semipreparative 
HPLC purification compound 13 (8.83 mg, 13.3 mmol, 19%) was obtained as 
colorless solid. 
1H-NMR (500 MHz, DMSO): δ = 12.88 (bs, 1H), 8.49 (bs, 1H), 8.15 (d, 3J = 8.4 
Hz, 1H), 7.90 (t, 3J = 5.4 Hz, 1H), 7.74 (d, 3J = 8.7 Hz, 2H), 7.41 (t, 3J = 7.4 Hz, 
1H), 7.13 (d, 3J = 8.5 Hz, 2H), 6.95 (d, 3J = 8.8 Hz, 2H), 6.83 (d, 3J = 8.5 Hz, 2H), 
6.50 (dd, 3J = 7.0 Hz, 4J = 2.4 Hz, 1H), 6.38 (d, 4J = 2.2 Hz, 1H), 4.43-4.38 (m, 
1H), 4.06-3.98 (m, 4H), 3.87 (s, 3H), 3.47-3.43 (m, 2H), 3.33-3.29 (m, 2H), 3.21-
3.17 (m, 2H), 2.77-2.71 (m, 2H), 2.41 (d, 2J = 15.4 Hz, 3J = 6.3 Hz, 1H), 2.09 (t, 
3J = 7.0 Hz, 2H), 2.04-1.98 (m, 2H), 1.87-1.81 (m, 2H), 1.55-1.46 (m, 4H). HPLC 
(10-90%, 15 min): tR = 4.63 min. MS (EI): 662.4 [m+H]+. 
 
 
 
 
 
 
 
 
 
 S24
(S)-3-(4-(3-(5-(4-((13S,20S)-13-((S)-2,6-bis(3-
phosphonopropanamido)hexanamido)-3,12,19,26-tetraoxo-28-phosphono-
20-(3-phosphonopropanamido)-5,8-dioxa-2,11,18,25-tetraazaoctacosyl)-1H-
1,2,3-triazol-1-yl)pentanamido)propoxy)benzamido)-4-(4-(3-((4-
methoxypyridin-2-yl)amino)propoxy)phenyl)butanoic acid (14) 
 
Prepared from 13 (2.55 mg, 3.85 µmol, 1 eq.) and (11S,18S)-11-((S)-2,6-bis(3-
(bis(benzyloxy)phosphoryl)propanamido)hexanamido)-26-(bis(benzyloxy)phos-
phorryl)-18-(3-(bis(benzyloxy)phosphoryl)propanamido)-10,17,24-trioxo-3,6-
dioxa-9,16,23-triazahexacosan-1-oic acid (7.10 mg, 3.85 µmol, 1 eq.) according 
to GP8 and deprotected according to GP7. After semipreparative HPLC 
purification compound 14 (1.65 mg, 1.1 µmol, 14%) was obtained as colorless 
solid. 
HPLC (10-90%, 40 min): tR = 10.66 min, MS (ESI): m/z = 1790.7 [m+H]+, 1788.8 
[m-H]-, 894.3 [(m-H)/2]-. HR-MS (ESI) (C73H117N15O29P42+): calc.: 895.85406, 
found: 895.85487; (C73H118N15O29P43+): calc.: 597.57180, found: 57180; 
(C73H114N15O29P4-): calc.: 1788.68628, found: 1788.67553. 
 
 
 
 
 
 
 
 
 
 S25
Dibenzyl(3-oxo-3-(prop-2-yn-1-ylamino)propyl)phosphonate (15) 
 
Prepared from 3-(bis(benzyloxy)phosphoryl)propanoic acid (334 mg, 1.0 mmol, 
1 eq.) and propargylamine (83 mg, 1.3 mmol, 1.3 eq) according to GP9. After 
semipreparative HPLC purification compound 15 (40.9 mg, 0.11 mmol, 11%) was 
obtained as yellow oil. 
RP-HPLC (10-90%, 30 min): Rt = 19.73 min. MS (ESI): m/z = 372.1 [m+H]+, 
394.2 [m+Na]+. 
 
 
(S)-Dibenzyl(3-((5-acetamido-6-oxo-6-(prop-2-yn-1-ylamino)hexyl)amino)-3-
oxopropyl)phosphonate (16) 
 
Prepared from  Fmoc-L-Lys(Alloc)-OH according the following reaction sequence:  
Loading of 110 mg resin (real loading: ~83 µmol, GP1), Fmoc deprotection 
(GP2), acetylation (GP10), Alloc deprotection (GP4), coupling of 3-
(bis(benzyloxy)phosphoryl)propanoic acid (GP3), cleavage from the resin (GP6) 
and coupling of propargylamine (GP9). After semipreparative HPLC purification 
compound 16 (19.40 mg, 35.8 µmol, 43%) was obtained as colorless oil. 
RP-HPLC (10-90%, 30 min): Rt = 17.64 min. MS (ESI): m/z = 542.3 [m+H]+, 
564.3 [m+Na]+. 
 
 
 
 
 
 
 
 S26
(S)-Dibenzyl(3-((6-acetamido-1-oxo-1-(prop-2-yn-1-ylamino)hexan-2-
yl)amino)-3-oxopropyl)phosphonate (17) 
 
Prepared from  Fmoc-L-Lys(Alloc)-OH according the following reaction sequence:  
Loading of 100 mg resin (real loading: ~66 µmol, GP1), Fmoc deprotection 
(GP2), coupling of 3-(bis(benzyloxy)phosphoryl)propanoic acid (GP3), Alloc 
deprotection (GP4), acetylation (GP10), cleavage from the resin (GP6) and 
coupling of propargylamine (GP9). After semipreparative HPLC purification 
compound 17 (15.0 mg, 27.7 µmol, 42%) was obtained as colorless oil. 
RP-HPLC (10-90%, 30 min): Rt = 18.03 min. MS (ESI): m/z = 542.3 [m+H]+, 
564.3 [m+Na]+. 
 
 
Dibenzyl(3-(((5S)-5-(3-(bis(benzyloxy)phosphoryl)propanamido)-6-oxo-6-
(prop-2-yn-1-ylamino)hexyl)amino)-3-oxopropyl)phosphonate (18) 
 
Prepared from  Fmoc-L-Lys(Fmoc)-OH according the following reaction 
sequence: Loading of 75 mg resin (real loading: ~49 µmol, GP1), Fmoc 
deprotection (GP2), coupling of 3-(bis(benzyloxy)phosphoryl)propanoic acid 
(GP3), cleavage from the resin (GP6) and coupling of propargylamine (GP9). 
After semipreparative HPLC purification compound 18 (19.65 mg, 24.1 µmol, 
49%) was obtained as yellow oil. 
RP-HPLC (10-90%, 12 min): Rt = 8.06 min. MS (ESI): m/z = 816.3 [m+H]+, 838.4 
[m+Na]+. 
 
 
 
 
 S27
Dibenzyl((8S,11S,18S)-8,18-diacetamido-2,9,17,24-tetraoxo-11-(prop-2-yn-1-
ylcarbamoyl)-3,10,16,23-tetraazahexacosan-26-yl)phosphonate (19) 
 
Prepared from  Fmoc-L-Lys(Alloc)-OH according the following reaction sequence: 
Loading of 1 g resin (real loading: ~660 µmol, GP1), Fmoc deprotection (GP2), 
coupling of Fmoc-L-Lys(Fmoc)-OH (GP3), Alloc deprotection (GP4), coupling of 
Fmoc-L-Lys(Alloc)-OH (GP3), Alloc deprotection (GP4), coupling of 3-
(bis(benzyloxy)phosphoryl)propanoic acid (GP3), Fmoc deprotection (GP2), 
acetylation (GP10), cleavage from the resin (GP6) and coupling of 
propargylamine (GP9). After semipreparative HPLC purification compound 19 
(123 mg, 139 µmol, 21%) was obtained as yellow oil. 
RP-HPLC (10-90%, 30 min): Rt = 15.36 min. MS (ESI): m/z = 882.3 [m+H]+, 
904.5 [m+Na]+. 
 
 
 
 
 
 
 
 
 
 
 
 S28
Dibenzyl-((8S,11S,18S)-8-acetamido-18-(4-(3-(bis(benzyloxy)phosphoryl)-
propanamido)butyl)-2,9,17,20-tetraoxo-11-(prop-2-yn-1-ylcarbamoyl)-
3,10,16,19-tetraazadocosan-22-yl)phosphonate (20) 
 
Prepared from  Fmoc-L-Lys(Alloc)-OH according the following reaction sequence: 
Loading of 1 g resin (real loading: ~692 µmol, GP1), Fmoc deprotection (GP2), 
coupling of Fmoc-L-Lys(Ac)-OH (GP3), Fmoc deprotection (GP2), acetylation 
(GP10), Alloc deprotection (GP4), coupling of Fmoc-L-Lys(Fmoc)-OH (GP3), 
Fmoc deprotection (GP2), coupling of 3-(bis(benzyloxy)phosphoryl)propanoic 
acid (GP3), cleavage from the resin (GP6) and coupling of propargylamine 
(GP9). After semipreparative HPLC purification compound 20 (234 mg, 
203 µmol, 29%) was obtained as yellow oil. 
RP-HPLC (10-90%, 30 min): Rt = 27.19 min. MS (ESI): m/z = 1156.5 [m+H]+, 
1178.6 [m+Na]+. 
 
 
 
 
 
 
 
 
 
 S29
Tetrabenzyl-((5S,12S,15S)-5-(4-acetamidobutyl)-15-(3-
(bis(benzyloxy)phosphoryl)propanamido)-3,6,14,21-tetraoxo-12-(prop-2-yn-
1-ylcarbamoyl)-4,7,13,20-tetraazatricosane-1,23-diyl)bis(phosphonate) (21) 
 
Prepared from  Fmoc-L-Lys(Alloc)-OH according the following reaction sequence: 
Loading of 1 g resin (real loading: ~687 µmol, GP1), Fmoc deprotection (GP2), 
coupling of Fmoc-L-Lys(Fmoc)-OH (GP3), Alloc deprotection (GP4), coupling of 
Fmoc-L-Lys(Alloc)-OH (GP3), Alloc deprotection (GP4), acetylation (GP10), 
Fmoc deprotection (GP2), coupling of 3-(bis(benzyloxy)phosphoryl)propanoic 
acid (GP3), cleavage from the resin (GP6) and coupling of propargylamine 
(GP9). After semipreparative HPLC purification compound 21 (266 mg, 
186 µmol, 27%) was obtained as yellow oil. 
RP-HPLC (10-90%, 30 min): Rt = 24.58 min. MS (ESI): m/z = 1430.7 [m+H]+. 
 
 
 
 
 
 
 
 
 
 
 
 
 S30
Dibenzyl-((5S,8S,15S)-23-(bis(benzyloxy)phosphoryl)-15-(3-(bis(benzyloxy)-
phosphoryl)propanamido)-5-(4-(3-
(bis(benzyloxy)phosphoryl)propanamido)-butyl)-3,6,14,21-tetraoxo-8-(prop-
2-yn-1-ylcarbamoyl)-4,7,13,20-tetraazatricosyl)-phosphonate (22) 
 
Prepared from Fmoc-L-Lys(Fmoc)-OH according the following reaction 
sequence: Loading of 1 g resin (real loading: ~580 µmol, GP1), Fmoc 
deprotection (GP2), coupling of Fmoc-L-Lys(Fmoc)-OH, Fmoc deprotection 
(GP2), coupling of 3-(bis(benzyloxy)phosphoryl)propanoic acid (GP3), cleavage 
from the resin (GP6) and coupling of propargylamine (GP9). After 
semipreparative HPLC purification compound 22 (224 mg, 131 µmol, 23%) was 
obtained as yellow oil. 
RP-HPLC (10-90%, 30 min): Rt = 27.19 min. MS (ESI): m/z = 1704.6 [m+H]+. 
 
 
Dibenzyl(3-(((S)-5-acetamido-6-(((S)-5-acetamido-6-oxo-6-(prop-2-yn-1-
ylamino)-hexyl)amino)-6-oxohexyl)amino)-3-oxopropyl)phosphonate (23) 
 
Prepared from  Fmoc-L-Lys(Alloc)-OH according the following reaction sequence: 
Loading of 45 mg resin (real loading: ~33 µmol, GP1), Alloc deprotection (GP4), 
coupling of Fmoc-L-Lys(Alloc)-OH (GP3), Alloc deprotection (GP4), coupling of 3-
(bis(benzyloxy)phosphoryl)propanoic acid (GP3), Fmoc deprotection (GP2), 
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acetylation (GP10), cleavage from the resin (GP6) and coupling of 
propargylamine (GP9). After semipreparative HPLC purification compound 23 
(5.14 mg, 6.6 µmol, 20%) was obtained as yellow oil.  
RP-HPLC (10-90%, 30 min): Rt = 15.39 min. MS (ESI): m/z = 712.4 [m+H]+, 
734.4 [m+Na]+. 
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